» Articles » PMID: 38704507

Monozygotic Twins Discordant for Schizophrenia Differ in Maturation and Synaptic Transmission

Abstract

Schizophrenia affects approximately 1% of the world population. Genetics, epigenetics, and environmental factors are known to play a role in this psychiatric disorder. While there is a high concordance in monozygotic twins, about half of twin pairs are discordant for schizophrenia. To address the question of how and when concordance in monozygotic twins occur, we have obtained fibroblasts from two pairs of schizophrenia discordant twins (one sibling with schizophrenia while the second one is unaffected by schizophrenia) and three pairs of healthy twins (both of the siblings are healthy). We have prepared iPSC models for these 3 groups of patients with schizophrenia, unaffected co-twins, and the healthy twins. When the study started the co-twins were considered healthy and unaffected but both the co-twins were later diagnosed with a depressive disorder. The reprogrammed iPSCs were differentiated into hippocampal neurons to measure the neurophysiological abnormalities in the patients. We found that the neurons derived from the schizophrenia patients were less arborized, were hypoexcitable with immature spike features, and exhibited a significant reduction in synaptic activity with dysregulation in synapse-related genes. Interestingly, the neurons derived from the co-twin siblings who did not have schizophrenia formed another distinct group that was different from the neurons in the group of the affected twin siblings but also different from the neurons in the group of the control twins. Importantly, their synaptic activity was not affected. Our measurements that were obtained from schizophrenia patients and their monozygotic twin and compared also to control healthy twins point to hippocampal synaptic deficits as a central mechanism in schizophrenia.

Citing Articles

miRNA profiling of hiPSC-derived neurons from monozygotic twins discordant for schizophrenia.

Rasanen N, Tiihonen J, Koskuvi M, Trontti K, Cheng L, Hill A Schizophrenia (Heidelb). 2025; 11(1):21.

PMID: 39966401 PMC: 11836399. DOI: 10.1038/s41537-025-00573-6.


NMDA Receptors in Neurodevelopmental Disorders: Pathophysiology and Disease Models.

Tumdam R, Hussein Y, Garin-Shkolnik T, Stern S Int J Mol Sci. 2024; 25(22).

PMID: 39596430 PMC: 11594297. DOI: 10.3390/ijms252212366.


Uncovering convergence and divergence between autism and schizophrenia using genomic tools and patients' neurons.

Romanovsky E, Choudhary A, Peles D, Abu-Akel A, Stern S Mol Psychiatry. 2024; 30(3):1019-1028.

PMID: 39237719 PMC: 11835745. DOI: 10.1038/s41380-024-02740-0.


Harnessing stem cell-based approaches for clinically meaningful discoveries in schizophrenia.

Lizano P, Karmacharya R Schizophr Res. 2024; 273:1-3.

PMID: 39209607 PMC: 11570341. DOI: 10.1016/j.schres.2024.08.006.


Altered Expression of PDE4 Genes in Schizophrenia: Insights from a Brain and Blood Sample Meta-Analysis and iPSC-Derived Neurons.

Burrack N, Yitzhaky A, Mizrahi L, Wang M, Stern S, Hertzberg L Genes (Basel). 2024; 15(5).

PMID: 38790238 PMC: 11121586. DOI: 10.3390/genes15050609.


References
1.
Cardno A, Gottesman I . Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am J Med Genet. 2000; 97(1):12-7. View

2.
Romanovsky E, Choudhary A, Peles D, Abu-Akel A, Stern S . Uncovering convergence and divergence between autism and schizophrenia using genomic tools and patients' neurons. Mol Psychiatry. 2024; 30(3):1019-1028. PMC: 11835745. DOI: 10.1038/s41380-024-02740-0. View

3.
Han E, Stevens C . Development regulates a switch between post- and presynaptic strengthening in response to activity deprivation. Proc Natl Acad Sci U S A. 2009; 106(26):10817-22. PMC: 2705571. DOI: 10.1073/pnas.0903603106. View

4.
Stern S, Sarkar A, Stern T, Mei A, Mendes A, Stern Y . Mechanisms Underlying the Hyperexcitability of CA3 and Dentate Gyrus Hippocampal Neurons Derived From Patients With Bipolar Disorder. Biol Psychiatry. 2019; 88(2):139-149. PMC: 7108962. DOI: 10.1016/j.biopsych.2019.09.018. View

5.
Balu D . The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment. Adv Pharmacol. 2016; 76:351-82. PMC: 5518924. DOI: 10.1016/bs.apha.2016.01.006. View